In “≥2nd line” (HR 0.92, 95% CI 0.84-1.01, p = 0.09, Fig. 7b), anti-PD-L1 (control group) (HR 0.99, 95% CI 0.89-1.10, p = 0.84, Fig. 7d) and head and neck squamous cell carcinoma (HR 0.96, 95% CI 0.79-1.15, p = 0.64, Fig. 7h) groups, there was no significant difference in PFS between ICI combination therapy and ICI monotherapy. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.